| |
NCT00650754 — Study of oral dehydroepiandrosterone (DHEA) to treat previously unexplained infertility
Preliminary findings and related research:
|
|
An infertility center in Canada independently conducted research that coincidentally matched the study completed at CHR, and combining both data sets yielded a patient data sample of sufficient size to state that DHEA supplementation significantly decreased the miscarriage rate in women with diminished ovarian reserve. |
| |
|
|
|
A paper published in 2007 at CHR (Barad et al., Obstet Gynecol 2007;109:1404-10) reported that approximately 50% of younger women (under age 41) suffer from premature ovarian aging (POA). Even though this suggests that POA is a very frequent finding in fertility centers, the diagnosis is unfortunately often overlooked. Especially if POA is not very advanced, the premature aging process is often misdiagnosed as so-called unexplained infertility. |
| |
|
|
|
This study investigates the effect of treatment with dehydroepiandrosterone (DHEA) on fertility outcomes among women with diminished ovarian reserve, and confirms the previously reported beneficial effects of DHEA supplementation on ovarian function in women with diminished ovarian reserve. |
|
Some women appear to have a gradual, yet premature, decline in ovarian function that is distinct from ovarian failure. In the author's experience, there is hope for successful pregnancy in these cases—with quick and correct diagnosis and the right treatment. |
|
The study set out to assess whether abnormal autoimmune function and number of triple CGG repeats on the FMR1 (fragile X) gene, both historically associated with risk toward premature ovarian senescence, represent independent risk factors. Conclusion: Abnormal autoimmune function and expansions in triple CGG repeats on the FMR1 gene represent distinctively different etiologies for premature ovarian senescence in infertile patients and may, indeed, constitute its two principal causes. |
| |
